{"entity":{"id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","aka":[],"tldr":"A phase 2 trial of ATL administration in hepatocellular carcinoma, run by Lukas Biomedical Inc., now recruiting.","summary":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT05304481 by Lukas Biomedical Inc., with 95 participants planned, started 2022-05-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: ATL administration.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05304481","url":"https://clinicaltrials.gov/study/NCT05304481"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05304481","phase":"2","setting":"A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment","sponsor":"Lukas Biomedical Inc.","enrolled":95,"outcomes":[]},"route":"/trials/nct05304481/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}